Prekovic Lab at UMC Utrecht

Chromatin-related factors and lineage plasticity

Computational Oncogenomics

News

05/09/2024

Our lab has recently published a collaborative paper in Nature with the van Rheenen group that uncovers the mechanisms by which mutations in mammary tissue are cleared, preventing tumorigenesis. 

05/09/2024

This month Danae Willboren, a wet-lab student, has successfully defended her thesis! Well done Danae and good luck in Paris.

25/07/2024

This month Tessa Mulder and Masa Milutinovic, our bioinformatics master's students, successfully defended their respective theses.! t was great having both of them in the lab, and we look forward to seeing them grow as scientists in the future!

29/07/2024

Our lab members attended the Dutch Lung Congress! Julia Scott was selected to present during the Chiesi Young Investigator session and received a prize of 400 euro in addition to this honour. See the impressions below, including Stefan’s commentary on the session he chaired:

For older news see News Archive.

Research

Transcription factors have for years been considered attractive targets in cancer therapeutic development. Emergence of specific drugs for targeting these proteins led to optimized use in cancer treatment, with many of these drugs becoming part of standard-of-care regiments. The nuclear receptor family of transcription factors is of particular interest, as their pharmacological targeting leads to growth suppression in both solid and liquid cancers. This is best exemplified in breast and prostate cancer, for which inhibitors of Estrogen and Androgen receptors are used to stop cancer growth/progression, and lymphoid cancers where activators of the Glucocorticoid receptors induce apoptosis. While targeting nuclear receptors is initially effective, all cancers will eventually adapt and become resistant to these therapies through various mechanisms that most often include re-activation of nuclear receptor signalling through various means. Therefore, target discovery, drug development and pre-clinical testing remain a constant clinically unmet need.

Glucocorticoid Receptor in Cancer

Glucocorticoids, a class of steroid hormones, have a complex relationship with cancer. While they can suppress the immune system and promote cancer growth, they can also induce apoptosis and inhibit cancer cell proliferation. The glucocorticoid receptor (GR) plays a key role in mediating these effects, and targeting the GR pathway may be a promising strategy for treating certain types of cancer. However, further research is needed to fully understand the role of glucocorticoids in cancer and to develop effective therapies that can exploit their anti-cancer effects.

Projects related to the glucocorticoid receptor in lung and breast cancer are supported by funding from the Dutch Cancer Foundation (KWF) and are done in collaboration with Zwart lab, Netherlands Cancer Institute.

STAG2, transcription factors and lineage determination

Lung cancer is deadly, with 83% of patients dying within 5 years of diagnosis. STAG2 loss in 20% of cases leads to poor survival and a mucinous cell-like state. Our research shows altered growth patterns and metabolic changes in STAG2-deficient lung cancer cells, with vulnerabilities to PARP and BRD inhibitors. We aim to study lineage maintenance in STAG2-deficient lung cancer and test the effectiveness of these inhibitors in pre-clinical models, with the goal of developing better therapies and diagnostics to improve patient outcomes. Hear more about this research line in Stefan’s research pitch here.

Projects related to the STAG2 function in lung cancer are funded by Alpe/d’Huiz and Bus Mulder Award.

Locus-specific regulation by transcription factors

Our research focuses on unraveling the mystery of how steroid hormone receptors (SHRs) regulate transcriptional activity. We use FACS-based genome-wide CRISPR screening to investigate the essential components of the SHR-recruited co-regulator complex that drive transcription following hormonal stimuli. Our findings reveal a functional cross-talk between PAXIP1 and STAG2, which are critical co-regulators of the Glucocorticoid Receptor (GR) complex. We demonstrate that PAXIP1 and STAG2 are required to maintain 3D-genome architecture and drive the GR transcriptional programme following hormonal stimuli. In lung cancer, PAXIP1/STAG2 loss enhances GR-mediated tumor suppressor activity by modifying local chromatin interactions. Overall, our research introduces PAXIP1 and STAG2 as novel co-regulators of GR, opening up new avenues for understanding transcriptional regulation in hormonal signaling (Mayayo-Peralta et al, 2023, NAR). 

Publications

Differential transcriptional invasion signatures from patient derived organoid models define a functional prognostic tool for head and neck cancer.

Haughton PD, Haakma W, Chalkiadakis T, Breimer GE, Driehuis E, Clevers H, Willems S, Prekovic S#, Derksen PWB#.Oncogene. 2024 Jun 28. doi: 10.1038/s41388-024-03091-4. Online ahead of print.PMID: 38942893

#denotes shared senior authorship

Recent publications

Unraveling the molecular interactions between α7 nicotinic receptor and a RIC3 variant associated with backward speech.

Pradhan A, Mounford H, Peixinho J, Rea E, Epeslidou E, Scott JS, Cull J, Maxwell S, Webster R, Beeson D, Dong YY, Prekovic S, Bermudez I, Newbury DF.Cell Mol Life Sci. 2024 Mar 12;81(1):129. doi: 10.1007/s00018-024-05149-8.PMID: 38472514

The 2023 generation.

Achinger-Kawecka J, Correa S, Hu J, Li G, Lindeboom RGH, Misale S, Monkkonen T, Nirmal AJ, Prekovic S, Sinha S, Trigos AS, Watson CJ.

all authors share correspondence

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

Prekovic S, Chalkiadakis T*, Roest M*, Roden D, Lutz C, Schuurman K, Opdam M, Hoekman L, Abbott N, Tesselaar T, Wajahat M, Dwyer AR, Mayayo-Peralta I, Gomez G, Altelaar M, Beijersbergen R, Győrffy B, Young L, Linn S, Jonkers J, Tilley W, Hickey T, Vareslija D, Swarbrick A, Zwart W.

*denotes shared first authorship

Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1-NDRG1 deregulation

Mayayo-Peralta I, Debets DO, Prekovic S, Schuurman K, Beerthuijzen S, Almekinders M, Sanders J, Moelans CB, Saleiro S, Wesseling J, van Diest PJ, Henrique R, Jerónimo C, Altelaar M, Zwart W. Mol Oncol. 2023 Oct 19. doi: 10.1002/1878-0261.13540. Online ahead of print.

Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.

Clarisse D, Prekovic S, Vlummens P, Staessens E, Van Wesemael K, Thommis J, Fijalkowska D, Acke G, Zwart W, Beck IM, Offner F, De Bosscher K. Cell Mol Life Sci. 2023 Aug 14;80(9):249. doi: 10.1007/s00018-023-04900-x.

Perturbations in 3D genome organization can promote acquired drug resistance.

Manjón AG, Manzo SG, Prekovic S, Potgeter L, van Schaik T, Liu NQ, Flach K, Peric-Hupkes D, Joosten S, Teunissen H, Friskes A, Ilic M, Hintzen D, Franceschini-Santos VH, Zwart W, de Wit E, van Steensel B, Medema RH. Cell Rep. 2023 Oct 31;42(10):113124. doi: 10.1016/j.celrep.2023.113124. Epub 2023 Sep 20.

Inhibiting the Glucocorticoid Receptor to Enhance Chemotherapy Response.

Prekovic S#, Zwart W. J Clin Oncol. 2023 Oct 20;41(30):4790-4793. doi: 10.1200/JCO.23.01195. Epub 2023 Aug 3.

#denotes corresponding authorship

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription

Mayayo-Peralta I, Gregoricchio S, Schuurman K, Yavuz S, Zaalberg A, Kojic A, Abbott N, Geverts B, Beerthuijzen S, Siefert J, Severson TM, van Baalen M, Hoekman L, Lieftink C, Altelaar M, Beijersbergen RL, Houtsmuller AB, Prekovic S#, Zwart W#. Nucleic Acids Res. 2023 Apr 18:gkad267. doi: 10.1093/nar/gkad267.

#denotes co-corresponding authorship

Team

        Group photo

Assistant professor / Group leader

Postdoc: Computational biology/Omics, Netherlands Cancer Institute, Netherlands

PhD: Biochemistry/Bioinformatics, KU Leuven, Belgium

BSc/MSc: Molecular Genetics, University of Belgrade, Serbia

Stefan Prekovic

Born and raised in a quaint Serbian town, I earned my BSc/MSc degrees from the University of Belgrade before relocating to Belgium. There, I joined Frank Claessens' lab, exploring the androgen receptor's role in diverse diseases. Later, as a postdoctoral researcher at the Netherlands Cancer Institute, I worked with Wilbert Zwart on investigating transcription factor action in various cancer types using omics, screening, and computational methodologies.

Born in Heraklion, Crete, Theofilos Chalkiadakis. began his academic journey at the University of Crete, earning a BSc in Biology. He then pursued an MSc in Bioinformatics from the joint program of Universiteit van Amsterdam and Vrije Universiteit Amsterdam in the Netherlands. Currently, Theofilos is focusing on utilizing computational strategies to unravel the complex actions of transcription factors, further advancing our understanding of their roles and impacts.

MSc: Bioinformatics, Universiteit van Amsterdam/Vrije Universiteit Amsterdam, Netherlands

BSc: Biology, University of Crete, Greece

PhD student

Theo Chalkiadakis

Born in Thessaloniki, Greece, Emmanouela Epeslidou recently completed her undergraduate MSci Biology studies at the University of Ioannina, where she majored in Biomolecular Sciences and Biotechnology. Emmanouela has amassed valuable research experience through internships at prestigious institutions like the Netherlands Cancer Institute and AHEPA General University Hospital. Her undergraduate thesis focused on investigating the potential anticancer activity of Pimozide in lung cancer mouse models.

Research Assistant

BSc/MSc: Biological Applications and Technology, University of Ioannina, Greece

Emma Epeslidou

Senior Research Assistant

BSc/MSc: Life Sciences (Microbiology), Hogeschool Utrecht

Mehmet Yilmaz

Mehmet Started his career at the Hubrecht Institute in Utrecht, where he worked on developing a proximity ligation technology. He then joined the startup company Cergentis where he helped develop the technology for commercial purposes. With a strong background in R&D, he has worked as a Senior Product Developer at Cergentis since 2012. Mehmet's expertise spans molecular genetic techniques, targeted enrichment strategies and NGS sequencing.

Julia Scott

Postdoctoral Fellow 

PhD: Medicine, University of Adelaide, Adelaide, Australia

MSc: Medical Science, Flinders University, Adelaide, Australia

BSc: Biology, University of Adelaide, Adelaide, Australia

Julia comes from Adelaide, Australia, where she earned her BSc (Advanced) degree in biochemistry and chemistry from The University of Adelaide, before undertaking an MSc (Honours) research year at Flinders University. She completed her doctoral training at The University of Adelaide, under the guidance of Prof. Lisa Butler, studying the role of lipid metabolism in prostate cancer progression. 

Stallmann Xaeviean

HBO Student

BSc: Inholland Amsterdam, Amsterdam, The Netherlands

PhD student (promotor: prof Wilbert Zwart; based at the NKI, Amsterdam)

MSc: Biology, Univeristy of Utrecht, Utrecht, Netherlands

BSc: Biology, Univeristy of Utrecht, Utrecht, Netherlands

Merel Roest

Minoo Molavi

Erasmus+ Masters Student

Joining in November

MSc: University of Milan, Milan, Italy

BSc: University of Milan, Milan, Italy

Alumni / Previously mentored

Isabel Mayayo-Peralta, PhD student (co-supervised by prof. Wilbert Zwart (promotor); based at the NKI; 2016-2023)

Roan van Scheppingen, research assistant (April - September 2024)

Nina Abbott, master student (project writing; 2023)

Loubna Ayadi, master student (literature review thesis; 2024)

Siem Jongsma, master student (bioinformatics literature review thesis; 2024)

Tessa Mulder, master student (bioinformatics internship; 2024)

Masa Milutinovic, master student (bioinformatics internship; 2024)

Danae Welboren, master student (wet-lab internship; 2023-2024)

Elise Mijderwijk, bachelor student (wet-lab short course internship, 2024)

Jamie Verkaart, bachelor student (wet-lab short course internship, 2024)